Commercialisation of healthcare in Germany: overview
A Q&A guide to the commercialisation of healthcare in Germany.
This Q&A provides an overview of the regulatory framework for the commercialisation of medical products in Germany. It covers the key requirements for manufacturing, advertising and selling drugs, medical devices, biological products and natural health products.
To compare answers across multiple jurisdictions, visit the commercialisation of healthcare Country Q&A tool.
This Q&A is part of the Commercialisation of Healthcare Global Guide. For a full list of jurisdictional Q&As visit www.practicallaw.com/healthcare-guide.
The healthcare system is characterised by different systems of market access for medical products and different reimbursement methods. These systems differ for pharmaceuticals and medical devices. In the EU, the decision to issue market authorisation is mainly dealt with at EU level, whereas the reimbursement decision is still a national issue. The German Drugs Act (AMG) sets out the regulatory framework for obtaining a marketing authorisation. The following are set out in the Social Code Book V (SGB V):
The legal framework of the organisation of the statutory health insurance system (GKV).
The responsibilities of the Federal Joint Committee (G-BA) and the other self-governing bodies.
The provisions for medical care.
Since about 85% of the population are insured within the GKV, the reimbursement decision is crucial for manufacturers of medical products. Regarding the GKV, legislation creates the legal framework for the medical self-governing bodies, such as associations (at a federal and regional level) of physicians, the statutory health insurance funds (SHI funds) and the German Hospital Federation, to formulate and implement in detail which healthcare services will be provided and under what conditions they are reimbursed.
The Federal Institute for Drugs and Medical Devices (BfArM) is competent for the authorisation of ﬁnished medicinal products, unless either the Federal Institute for Vaccines and Biomedicines (Paul-Ehrlich- Institut) (PEI) or the Federal Ofﬁce of Consumer Protection and Food Safety (BVL) are competent. The PEI is competent for (section 77, AMG):
Bone marrow preparations.
Gene transfer medicinal products.
Somatic cell therapy products.
Xenogenic cell therapy products.
Blood components manufactured using genetic engineering.
The BVL is responsible for medicinal products that are intended for administration to animals.
Most pharmaceuticals are now approved at EU level by the European Medicines Agency.
The G-BA is an association of all relevant parties of the statutory healthcare sector and, therefore, the most relevant regulatory body in the system. It represents:
The G-BA regulates detailed reimbursement matters as it issues directives about relevant questions and determines the beneﬁts package of the GKV. The Federal Ministry of Health has supervisory control of the G-BA.
For more information on the BfArM see box: The regulatory authorities.
The market introduction of all medicinal products, medical devices and other medical products is regulated on different scales. Pharmaceuticals must go through a sophisticated approval procedure, and the reimbursement decision represents another hurdle for medicinal products.
Currently, most pharmaceuticals are approved at EU level by the European Medicines Agency, rather than at the national level by the Federal Institute for Drugs and Medical Devices.
Medical devices must go through the conformity assessment procedure to obtain a CE mark. They can then be placed on the market.
All other products (for example biological and homeopathic preparations) must be approved in the same way as medicinal products, but with certain specificities and by other authorities.
A manufacturing licence from the competent local authority is generally required for the commercial manufacturing of (section 13, German Drugs Act (AMG)):
Active substances that are of human, animal or microbial origin or are manufactured using genetic engineering.
Other substances of human origin intended for the manufacture of medicinal products.
Manufacturing includes the production, preparation, processing, transfilling, pre-packaging, marking and release of a medicinal product. An authorisation must be granted if the manufacturer comply with all applicable requirements.
No manufacturing licence is required for blood and tissues, which require a specific authorisation and are subject to specific rules. In addition, a licence is not required for the procurement and laboratory tests of autologous blood for the manufacture of biotechnologically processed tissue products, tissue preparations and reconstitutions, provided that these are not intended for use in clinical trials.
Owners of pharmacies are also exempt from the requirement of a manufacturing licence for:
Manufacturing medicinal products within the scope of the normal operation of a pharmacy.
Reconstituting or packaging (including labelling) medicinal products intended for clinical trials, provided they comply with the trial protocol.
In addition, the following persons do not generally need a manufacturing licence:
Entities responsible for hospitals, in relation to medicinal products intended for clinical trials, provided they comply with the trial protocol.
Veterinarians operating a veterinary practice.
Wholesalers decanting, packaging or labelling medicinal products without altering them.
Retailers with expert knowledge (as defined in section 50 of the German Drugs Act), which decant, package or label medicinal products without altering them for direct distribution to consumers.
Manufacturers of active substances that are intended for use in the manufacture of medicinal products under a procedure described in the homeopathic section of the pharmacopoeia.
In addition to the regulatory system for market authorisation and market access discussed below, there is also a tight legal framework for advertising medical products. The legal requirements for marketing activities of pharmaceutical companies addressed to healthcare professionals or the general public are set out in the Advertisement of Medicinal Products Law (HWG). However, a marketing activity generally falls within the scope of the HWG only if the relevant activity is product-related and intended to increase the sales of a respective product. Provided the marketing activity is solely company-related, the rules of the Act against Unfair Competition (Gesetz gegen den unlauteren Wettbewerb) (UWG) are applicable. Finally, the AMG also imposes legal requirements for interactions with healthcare professionals and patient organisations.
Several industry guidelines also apply to product or company-related marketing activities of pharmaceutical companies, whether addressed to healthcare professionals or the general public. In particular, the following are relevant:
The Code of Conduct of the Drugs and Co-operation in the Healthcare Sector Association (Arzneimittel und Kooperation im Gesundheitswesen e.V.) (AKG) (AKG Code), issued by the German Pharmaceutical Industry Association (BPI).
The FSA Code of Conduct of Healthcare Professionals, issued by the Association of Research-Based Pharmaceutical Companies (VfA).
The industry guidelines discussed below are binding for members of the BPI and the VfA, and compliance is monitored and sanctioned by the Voluntary Self-Regulation for the Pharmaceutical Industry Association (Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V.) (FSA) and the AKG arbitration board. Even if a pharmaceutical company is not a member of the BPI or the VfA, these regulations must be observed by pharmaceutical companies, as these industry guidelines serve as a means of interpretation for the courts when assessing whether or not a marketing activity infringes the applicable legal provisions. The industry guidelines are speciﬁc and detailed on the activities in the pharmaceutical industry. Therefore, it is expected that judges use the conclusive guidelines to assess whether a certain practice in the pharmaceutical industry infringes the general legal provisions (that also apply to other industry sectors).
Both the AMG and the Social Code Book V (SGB V) set out the regulatory framework for obtaining a marketing authorisation and placing medicines on the market. A finished medicinal product can only be placed on the market after a marketing authorisation has been granted by the German Higher Federal Authority or the European Commission (section 21, paragraph 1, AMG). Placing on the market is defined as the (section 4, paragraph 17, AMG):
Keeping in stock for sale or for other forms of supply.
Exhibition and offering for sale.
Distribution to others.
The legal requirement to obtain an authorisation before placing the medicinal product on the market also applies also to (section 21a, paragraph 1, AMG):
Tissue preparations that are not manufactured in an industrial process.
The essential processing procedures that are sufﬁciently well known in the EU.
The effects and side effects that are known and evident from scientiﬁc data.
As well as the AMG, the Good Manufacturing Practice, which is a relevant legal prerequisite for the placing of medicines on the market, is laid down in certain national directives, such as the German Medicinal Products and Active Ingredients Manufacturing Decree.
The most relevant procedure for obtaining a marketing authorisation for human medicinal products is the national authorisation procedure, which is applicable to ﬁnished medicinal products (section 21, paragraph 1, AMG). Finished medicinal products are (section 4, paragraph 1, AMG):
Medicinal products that are first manufactured and then placed on the market in packaging intended for distribution to the consumer.
Other medicinal products intended for distribution to the consumer, where any form of industrial process is used to prepare it.
Medicinal products that are produced commercially, except in pharmacies.
In addition, if the pharmaceutical manufacturer applies for a marketing authorisation in more than one member state (provided that the respective medicinal product does not fall within the scope of the Regulation (EC) 726/2004 on the authorisation and supervision of medicinal products and establishing a European Medicines Agency (EMA Regulation)) and chooses Germany as the reference member state, the decentralised procedure (DCP) and the mutual recognition procedure (MRP) apply (section 25b, AMG). The DCP member states' standard operating procedures or the Best Practice Guide for DCP and MRP, issued by the Coordination Group are also relevant.
For doctors, the approval is also an indication of the probability that the drug is effective in the speciﬁed indication and therefore can be prescribed. However, the drug is only reimbursable by the statutory health insurance (SHI) for the ﬁrst year after market access. This is a major amendment under the Pharmaceuticals Market Reorganisation Act (Arzneimittelmarkt-Neuordnungsgesetz) (AMNOG). After the ﬁrst year, the reimbursement decision depends on a legal instrument. Depending on whether or not the active substance is new, some legal instruments exist, in particular for the outpatient sector, which have a direct impact on the price setting of medicines within the SHI. These instruments are stipulated in the SGB V, as follows:
The reference price system (section 35, paragraph 1, SGB V).
The early beneﬁt assessment (section 35a, SGB V).
The efﬁciency principle (section 2, paragraph 12, SGB V).
The therapy information (section 92, paragraph 2, SGB V).
A reference price system can be set by the Federal Joint Committee (G-BA) for medicines with:
The same active substance.
Therapeutically and pharmacologically comparable active substances.
Therapeutically comparable effects.
The reference price is based on the price of all products of the group into which the medicines are categorised and constitutes the maximum amount being reimbursed for the respective medicines by the SHI. If the price has been set at a higher level by the pharmaceutical company, the difference must be paid by the patient receiving the medicine. However, according to the Basis for Decision-Making by the Subcommittee-Medicines for Deﬁning Reference Prices dated 19 July 2007, no reference price should be set for patented medicines based on a new principle and deemed to represent a signiﬁcant therapeutic advance.
The AMNOG proposes a new form of price setting for innovative medicinal products and sets new conditions for pricing and reimbursement of medicinal products. Since 2011, the reimbursement of a new medicinal product has been aligned on its therapeutic value. According to the AMNOG, the value of an innovative medicinal product is determined in comparison with existing therapies. A higher price can only be negotiated with the National Association of Statutory Health Insurance Funds (GKV- Spitzenverband) (GKV-SV) if an additional beneﬁt can be proven to the G-BA for existing therapies. Medicinal products without any additional beneﬁt are only reimbursed at the level of comparable products or therapies.
The efficiency principle can also be speciﬁed or deﬁned by therapy information. The result is that the medicine for which therapy information exists (issued by the G-BA) is only reimbursed for certain therapy application. The Drug Price Ordinance sets out certain conditions for the pricing of medicines.
There is a list of medicinal products that can be placed on the market without being approved (section 21, paragraph 2, AMG). The most relevant exemption to the rule that medicines must only be placed on the market after a marketing authorisation has been granted is set out in the AMG (section 21, paragraph 2, No. 1). This applies to products for which the essential manufacturing stages are carried out in a pharmacy. Similarly, no approval is needed for products for which up to 100 packages are produced in one day that are dealt with within the framework of the pharmacy operating licence.
Market authorisation for generic pharmaceuticals has only been possible since 2005, (section 24b, paragraph 5, German Drugs Act ( AMG)). The generic drug only needs to be similar, not identical, to the patented product. However, the manufacturer must submit documentation of pre-clinical and clinical trials.
Biomedical scientiﬁc progress allows the development of advanced therapy medicinal products such as:
Somatic cell therapy.
Therefore, a special legal category of biologics was created for "advanced therapy medicinal products" under Article 2, paragraph 1(a) Regulation (EC) 1394/2007 on advanced therapy medicinal products, which are (section 4, paragraph 9, AMG):
Somatic cell therapy.
Tissue engineered products.
These include drugs from substances of biological origin, as well as tissue preparations, blood preparations and immunological medicinal products. Since the Regulation directly binds all member states, special German regulations no longer apply.
The competent authorities for regulating the manufacture and sale of drugs are the Federal Institute for Drugs and Medical Devices (BfArM) and the Federal Joint Committee (G-BA) (see Question 1).
Advertising is mainly regulated through the relevant courts proceedings regarding competition law cases. In practice, authorities do not regulate violations of the pharmaceutical advertising law.
If a pharmaceutical has been approved in another EU member state, the manufacturer can apply for approval by the mutual recognition procedure. Basic arrangements for implementing the mutual recognition procedure that are laid down in Directive 2001/83/EC on the Community code relating to medicinal products for human use (Code for Human Medicines Directive) have been made in all member states. To be eligible for this procedure, a medicinal product must have already received a marketing authorisation in one member state.
The applications submitted must be identical and all member states must be notiﬁed of them. Once a member state decides to evaluate the medicinal product (at which point it becomes the "reference member state") it then notiﬁes this decision to the other member states (which then become the "concerned member states") to whom applications have also been submitted. Concerned member states then suspend their own evaluations and wait for the reference member state's decision on the product. Less information has to be provided since the reference member state examines all documents and grants the approval. The concerned member states should refer to this approval unless there are severe safety restrictions.
Medicines can be imported into Germany if they cover the provisions of the German Drugs Act (AMG) or if they are registered according to Regulation (EC) 726/2004 on the authorisation and supervision of medicinal products and establishing a European Medicines Agency (EMA Regulation). If they are not approved or registered accordingly, it is not permissible to sell or buy them in Germany (section 73, AMG), even if there are comparable drugs available.
However, there are some exemptions for personal use and travel needs. In addition, small amounts of drugs can be ordered from foreign countries to a German-based pharmacy if the active substance is not available in Germany (section 73, paragraph 3, AMG).
Generally, product-related advertisements (section 3, Advertisement of Medicinal Products Law (HWG)) and company-related advertisements (section 5, Act against Unfair Competition ( UWG)) addressed to healthcare professionals must not be misleading or unfair, which means the promotional statement must be correct and, if necessary, veriﬁable. HWG and UWG contain concrete examples of misleading or unfair competition. For product-related advertisements, most importantly, the law requires that the promoted medicinal product must not be described as having therapeutic efﬁcacy or effects that it does not possess, and that the advertisement does not give a false impression that success is guaranteed or that the recommended use has no side effects (section 3, Nos. 1 and 2, HWG). A respective list of legal examples is set out in the UWG, which applies to company-related advertising statements (sections 4 and 5, UWG). Other important principles applying to product-related advertisements are that:
The advertisement must always mention the mandatory information regarding the promoted medicine.
The promoted indications must be in line with the marketing authorisation, the summary of product characteristics and the package leaﬂet.
The promotional statement addressed to the general public must not be misleading or unfair and this also covers healthcare professionals. However, further legislative provisions apply to enhance the protection of the general public, as the public is considered to have no (substantial) medical knowledge. For example, the HWG sets out that the advertising of prescription-only medicines is prohibited to the general public (section 10, HWG). This prohibition ensures that the healthcare professionals decide independently on the prescription of certain medicines based solely on medical considerations that are not inﬂuenced by the patient. In addition, the HWG contains a list of examples of advertisements that must not be directed to people other than healthcare professionals, as they are potentially misleading or manipulative. These include advertisements containing:
Scientiﬁc or professional publications.
Statements alleging that the medicine is recommended, tested or used by healthcare professionals.
Foreign or professional terminology, where these have not become part of general German vocabulary.
Publications that suggest self-diagnosis and treatment by the advertised medicinal product.
Under Directive 93/42/EEC concerning medical devices (Medical Devices Directive), a medical device is an instrument, apparatus, appliance, software, material or other article that is used alone or in combination, including software specifically used for diagnostic or therapeutic purposes, that the manufacturer intends for use in human beings. For these devices, the German Medical Devices Act implements the requirements of EU directives.
Generally, medical devices must be approved. However, there are no comparable restrictions regarding clinical testing or additional beneﬁt. If medical devices have passed the conformity assessment procedures, they obtain a CE mark. If the CE mark and the summary of product characteristics are submitted in the respective member states' language, the device can enter the market. No restrictions can be established within any single member state, and the CE mark constitutes the market authorisation. The core legal framework consists of three directives:
Directive 90/385/EEC on active implantable medical devices (Active Implantable Medical Devices Directive).
Medical Devices Directive.
Directive 98/79/EC on in vitro diagnostic medical devices (IVD Directive).
These are aimed at providing a high level of protection of human health and safety, and the good functioning of the single market. These three main directives have been supplemented over time by several modifying and implementing directives, including the last technical revision brought about by Directive 2007/47/EC.
According to these directives and the German Medical Devices Act, a class system differentiates four risk classes, which are set out in Annex IX of Directive 93/42/EEC:
All non-invasive devices are in class I, unless another class refer to such devices.
The devices in class IIa or IIb are as follows:
all non-invasive devices intended for channelling or storing blood, body liquids or tissues, liquids or gases for the purpose of eventual infusion, administration or introduction into the body are generally in class IIa; and
all non-invasive devices intended for modifying the biological or chemical composition of blood, other body liquids or other liquids intended for infusion into the body generally are in class IIb.
All invasive devices are generally in class III.
The requirements for the conformity assessment procedures differ depending on the respective classes. Products in class I must pass the conformity assessment procedures at the manufacturer's own risk and prepare documentation, including risk management, to be submitted to the authorities if requested. The state authority must also regularly certify the products in classes IIa, IIb and III. However, the manufacturer remains in charge of safety risks of the product and retains ownership. The manufacturer is the person or company that ﬁrst places the product on the market, regardless of the producer.
The EU legal framework is currently being revised, and will probably be centralised further. Therefore, the three directives mentioned above will be replaced. On 26 September 2012, the European Commission adopted a Proposal for a Regulation on medical devices and a Proposal for a Regulation on in vitro diagnostic medical devices that, once adopted by the European Parliament and by the Council, will replace the existing three medical devices directives. Instead, these regulations will be directly binding on member states and all applicants. In contrast, the previous directives had to be implemented into each of the national legal systems, which allowed different interpretations across EU member states.
One of the main amendments is to make clinical testing to be obligatory in all member states in order to obtain a market authorisation.
The approval decision is made by the notified body, that is the Technical Inspection Association (TUV). However, the CE mark of all EU-notified bodies is recognised.
Regarding reimbursement, the Federal Joint Committee (G-BA) decides whether a medical device must be reimbursed if a benefit assessment is applied for.
See Question 13.
The sale of medical devices depends on the classification of the device. If introduced to the outpatient sector, a device can only be reimbursed if there is a specific code number in the fee schedule of office-based doctors. In the inpatient sector, any device can be reimbursed under the diagnosis-related group (DRG) system, unless the G-BA decides that no reimbursement for this device was possible.
For treatment methods, benefit assessments by the G-BA and the Institute for Quality and Efficiency in Healthcare (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen) (IQWiG) also involve decisions about reimbursement.
Notified bodies are in charge of the manufacture decision. The Federal Joint Committee (G-BA) gives the decision on reimbursement (however, the statutory health insurance (SHI) is responsible for individual cases of reimbursement).
There is no authority specifically responsible for regulating advertising of medical devices.
Competition law cases are, in practice, decided by the courts.
As the CE mark is acknowledged in all member states of the EU, there are no further restrictions on single member states beyond the requirement to submit the CE mark and translate the summary of the product characteristics. For reimbursement, the manufacturer must apply to the Federal Joint Committee (G-BA) (See Question 9).
It is possible to sell and buy devices from all EU member states provided that they have CE marks. To achieve reimbursement in Germany, internationally produced medical devices must be introduced to the European system, as the statutory health insurance (SHI) does not directly refund products, but refunds the implantation procedure.
The restrictions on advertising of drugs apply equally to medical devices (section 1, No. 1a, Advertisement of Medicinal Products Law (HWG)) (see Question 8). However, there are a number of exceptions, as not all of these statutes are suitable for medical devices. It is permissible to promote medical devices to the public (in contrast to the regulation for pharmaceuticals) in certain cases because there is less danger that patients will avoid doctors and of self-diagnosis (section 11, paragraph 1, sentence 2, HWG). The HWG only applies to:
Advertisements that lead to the assumption that health risks will occur if a medical device is not used.
Cases where medical devices are offered in connection with advertising events.
Cases of publications where the promotional purpose is not clearly recognisable.
The HWG also applies to publications of third parties that are conducted in misleading ways and advertisements that are only addressed to children below the age of 14 years.
Biological products are not clearly defined under German or EU legislation. They can be identified as pharmaceuticals whose active substances are gained from recombinant cell cultures. Apart from examples of biologics, there is no legally binding deﬁnition of such products. There is also a catalogue of pharmaceuticals manufactured by biotechnological procedures in the Annex to Regulation (EC) 726/2004 on the authorisation and supervision of medicinal products and establishing a European Medicines Agency (EMA Regulation). These pharmaceuticals must be marketed according to the centralised procedure before the European Medicines Agency (EMA), not national authorities.
Regarding the legal regulation of biologics, national rules only apply to the regulatory outlines. The EMA Regulation sets the legal framework regarding market authorisation and market access of all preparations that contain a biologic substance. According to the EMA Regulation, a biological product can be seen as one of the active substances produced by or extracted from a biological system, and requires, in addition to physico-chemical testing, biological testing for full characterisation. The characterisation of a biological medicinal product is a combination of testing the active substance and the ﬁnal medicinal product, together with the production process and its control. Regarding the production process, a biological product can be derived from biotechnology or derived from other new technologies. It can also be prepared using more conventional techniques, as is the case for blood or plasma-derived products and a number of vaccines.
Therefore, a biological product can consist of:
Entire micro-organisms or mammalian cells.
Nucleic acids or proteinaceous or polysaccharide components originating from a microbial, animal, human or plant source.
For its mode of action, a biological product can be:
A therapeutic medicinal product.
An immunological product.
Gene transfer material.
Cell therapy material.
The legal framework relevant to pharmaceuticals also applies to reimbursement (see Question 3, Manufacturing).
There are no specific requirements for advertising. They are generally the same as for medicinal products (see Question 3, Advertising).
If a biological product is approved for use in human beings, the same legal framework applies as for pharmaceuticals (see Question 3, Sale).
The Federal Institute for Vaccines and Biomedicines (Paul-Ehrlich- Institut) (PEI) or the Federal Ofﬁce of Consumer Protection and Food Safety (BVL) are the competent authorities. The PEI is competent for (section 77, German Drugs Act (AMG)):
Bone marrow preparations.
Gene transfer medicinal products.
Somatic cell therapy products.
Xenogenic cell therapy products.
Blood components manufactured using genetic engineering.
The same applies as for pharmaceutical products (see Question 6).
There are no speciﬁc regulations concerning the advertising of biological products. Therefore, the requirements for pharmaceuticals also apply to biological products (see Question 13). The Advertisement of Medicinal Products Law (HWG) regulates the advertising of "other products", such as cosmetic or food products, and therefore applies to biological products.
Natural health products
Under the law, natural health products are not classiﬁed into a deﬁnable group of medical products. However, certain regulations exist for homeopathic and traditional products, as well as dietary or food products, regarding the speciﬁc procedures to be applied to patients.
Regarding vitamins and dietary products, there is a sophisticated legal framework that distinguishes between pharmaceutical and food products. Dietary and dietary supplement products are regularly classiﬁed as food products, and therefore do not need to be approved under the system for pharmaceuticals. A clear line cannot be drawn between these two sectors as the distinction between food and pharmaceutical products depends on individual cases that are covered by the relevant EU regulations' terminology. However, the following criteria are applied to distinguish pharmaceuticals from food products:
Deﬁnition of purpose.
Generally, natural health products must be approved (section 21, German Drugs Act (AMG)). Quality, effectiveness and safety must be demonstrated for all marketed drugs based on pharmacologic and clinical studies, as well as all data available on the speciﬁc procedures to be applied to patients. However, traditional products do not have to be approved but registered (section 39a–d, AMG). Quality, effectiveness and safety must be proven, but clinical trials are not required.
In addition, non-prescription homeopathic preparations must be registered (sections 38 and 39, AMG). They can also be approved on the manufacturer's choice (section 21, AMG). However, prescription drugs must be approved rather than just registered. If they are only registered, they must be declared as homeopathic and cannot be advised for certain indications. Studies on safety must be submitted, but the manufacturer does not need to prove the effectiveness of a registered homeopathic product.
If homeopathic products are approved under section 21 of the AMG, the homeopathic therapeutic beneﬁt must be proven and all documents must be submitted. Therefore, the homeopathic therapeutic beneﬁt shouldnot to be mistaken with the additional beneﬁt to be proven for pharmaceuticals under the early beneﬁt assessment. If the manufacturer obtains market authorisation, the area of application must be indicated as the approval is only effective for the relevant area of application. If the homeopathic product is only registered, no indication can be speciﬁed.
The manufacturer cannot advertise a homeopathic drug with an indication unless it is registered and not approved (section 5, Advertisement of Medicinal Products Law (HWG)). If the product is approved, the manufacturer must indicate the areas of application and must not indicate that the product is homeopathic to avoid confusion.
There are no further regulations concerning advertising of other natural health products. Therefore, the requirements that apply to pharmaceutical products also apply to those products that are determined to cure, and so are classiﬁed as pharmaceutical products (section 2, AMG). As the HWG regulates the advertising of "other products", such as cosmetic or food products (even if they are not classiﬁed as pharmaceutical products), and therefore applies to natural health products.
Natural health products are mostly over-the-counter preparations and are therefore not reimbursable.
The restrictions mentioned in Question 8 apply to natural health products depending on the product in question, as there is no deﬁnable group of natural health products, although regulations differ depending on the respective preparations (see Question 19).
The federal government is currently discussing further amendments to the Pharmaceuticals Market Reorganisation Act (Arzneimittelmarkt-Neuordnungsgesetz). Additionally, in 2017, a new law will introduce minor changes to market access and pricing legislation for pharmaceuticals, including provisions on:
The confidentiality of reimbursement prices.
Price caps on high launch prices.
Support for the development of new antibiotics.
The regulatory authorities
Federal Institute for Drugs and Medical Devices (BfArM)
Principal responsibilities. The BfArM is the competent authority for the marketing authorisation of pharmaceuticals. However in practice, market authorisations are mainly applied for at EU level, to the European Medicines Agency.
Federal Joint Committee
Principal responsibilities. The Federal Joint Committee is the main authority for reimbursement decisions and for enforcing the Pharmaceuticals Market Reorganisation Act procedure.
German Drugs Act
Description. This website is maintained by the Federal Ministry of Health and is updated regularly. All recent amendments are included. Only the German Drugs Act (AMG) is available in English. All other regulations are only available in German.
Pr Alexander Ehlers, Partner
Ehlers, Ehlers & Partner
Professional qualifications. Germany, Lawyer
Areas of practice. Medical law; pharmaceutical law; life sciences.
Dr Christian Rybak, Partner
Ehlers, Ehlers & Partner
Professional qualifications. Germany, Lawyer
Areas of practice. Life sciences; healthcare sector; pharmaceutical and medical devices.
Dr Anke Moroder, Senior Associate
Ehlers, Ehlers & Partner
Professional qualifications. Germany, Lawyer
Areas of practice. Life sciences.